Description
What it is
Dual GIP / GLP-1 receptor agonist. EU-authorized for type-2 diabetes and chronic weight management.
Mechanism
Tirzepatide is the first dual GIP/GLP-1 receptor agonist, activating both incretin pathways to enhance glucose-dependent insulin secretion, suppress glucagon and slow gastric emptying.
Specifications
- Peptide content: 100mg / vial
- HPLC purity: ≥99.3%
- Form: Lyophilized powder
- Storage: 2–8°C, protected from light
- Shipping: Cold-chain dispatch from EU warehouse, same-day if ordered before 14:00 CET
Certificate of Analysis
Every batch ships with a downloadable Certificate of Analysis showing HPLC purity, mass-spec identity confirmation, and microbial/endotoxin pass results.






Reviews
There are no reviews yet.